David Shrom

1.3k total citations
22 papers, 923 citations indexed

About

David Shrom is a scholar working on Immunology, Dermatology and Economics and Econometrics. According to data from OpenAlex, David Shrom has authored 22 papers receiving a total of 923 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Immunology, 7 papers in Dermatology and 6 papers in Economics and Econometrics. Recurrent topics in David Shrom's work include Psoriasis: Treatment and Pathogenesis (15 papers), Dermatology and Skin Diseases (7 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). David Shrom is often cited by papers focused on Psoriasis: Treatment and Pathogenesis (15 papers), Dermatology and Skin Diseases (7 papers) and Health Systems, Economic Evaluations, Quality of Life (6 papers). David Shrom collaborates with scholars based in United States, Germany and Canada. David Shrom's co-authors include Ruiben Feng, Joe Z. Tsien, Bryce L. Sopher, Ya‐Ping Tang, Seong‐Hun Kim, George M. Martin, Ronald B. Langdon, Sangram S. Sisodia, Claire Rampon and Gregory W. Schwartz and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Neuron and SHILAP Revista de lepidopterología.

In The Last Decade

David Shrom

21 papers receiving 906 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Shrom United States	14	336	256	254	219	199	22	923
Anna Dellarole United States	14	98 0.3×	155 0.6×	236 0.9×	160 0.7×	4 0.0×	17	875
Alexandra Kotsiari Germany	11	149 0.4×	89 0.3×	155 0.6×	361 1.6×	6 0.0×	16	941
Daniel Abebe United States	24	64 0.2×	151 0.6×	375 1.5×	132 0.6×	5 0.0×	64	1.3k
Elías Utreras Chile	18	63 0.2×	223 0.9×	185 0.7×	64 0.3×	13 0.1×	27	806
Yanqing Yin China	15	113 0.3×	109 0.4×	260 1.0×	104 0.5×	8 0.0×	27	969
Jan Thöne Germany	18	204 0.6×	86 0.3×	152 0.6×	56 0.3×	4 0.0×	35	908
Masamichi Satoh Japan	13	160 0.5×	281 1.1×	606 2.4×	31 0.1×	9 0.0×	17	997
Lubov Nathanson United States	22	133 0.4×	120 0.5×	187 0.7×	87 0.4×	5 0.0×	58	1.3k
Ajay Ravindranathan United States	12	21 0.1×	105 0.4×	351 1.4×	44 0.2×	33 0.2×	17	927
Beatrice Paradiso Italy	17	16 0.0×	70 0.3×	394 1.6×	178 0.8×	17 0.1×	36	966

Countries citing papers authored by David Shrom

Since Specialization

Citations

This map shows the geographic impact of David Shrom's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Shrom with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Shrom more than expected).

Fields of papers citing papers by David Shrom

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Shrom. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Shrom. The network helps show where David Shrom may publish in the future.

Co-authorship network of co-authors of David Shrom

This figure shows the co-authorship network connecting the top 25 collaborators of David Shrom. A scholar is included among the top collaborators of David Shrom based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Shrom. David Shrom is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leonardi, Craig L., Kristian Reich, Peter Foley, et al.. (2020). Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled Trials. Dermatology and Therapy. 10(3). 431–447. 45 indexed citations

Blauvelt, Andrew, Craig L. Leonardi, Mark Lebwohl, et al.. (2020). 16007 Ixekizumab demonstrated longer medication persistence than other biologics in the treatment of psoriasis patients: Results from IBM MarketScan databases. Journal of the American Academy of Dermatology. 83(6). AB168–AB168. 1 indexed citations

Puig, L., Baojin Zhu, Russel Burge, et al.. (2020). Early Treatment Targets for Predicting Long-term Dermatology Life Quality Index Response in Patients with Moderate-to-Severe Plaque Psoriasis: A Post-hoc Analysis from a Long-term Clinical Study.. PubMed. 13(10). 18–22. 2 indexed citations

Shrom, David, et al.. (2019). Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA: Results from a Cross-Sectional Patient Survey. Dermatology and Therapy. 9(4). 785–797. 33 indexed citations

Merola, Joseph F., et al.. (2019). Patient Perspective on the Burden of Skin and Joint Symptoms of Psoriatic Arthritis: Results of a Multi-National Patient Survey. Rheumatology and Therapy. 6(1). 33–45. 24 indexed citations

Gladman, Dafna D., Ana‐Maria Orbai, James Cheng‐Chung Wei, et al.. (2019). Ixekizumab and complete resolution of enthesitis and dactylitis: integrated analysis of two phase 3 randomized trials in psoriatic arthritis. Arthritis Research & Therapy. 21(1). 38–38. 30 indexed citations

Warren, Richard B., Melinda Gooderham, Russel Burge, et al.. (2019). Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16 weeks: Results from a network meta-analysis. Journal of the American Academy of Dermatology. 82(5). 1138–1149. 44 indexed citations

Yosipovitch, Gil, et al.. (2019). Assessing the Impact of Improvements in PASI and Itch Scores on Patients’ Quality of Life in the Treatment of Psoriasis. Acta Dermato Venereologica. 99(11). 1031–1032. 7 indexed citations

Blauvelt, Andrew, Mark Lomaga, Russel Burge, et al.. (2019). Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial. Journal of Dermatological Treatment. 31(2). 141–146. 13 indexed citations

10.

Menter, Alan, Richard B. Warren, Richard G. Langley, et al.. (2017). Efficacy of ixekizumab compared to etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis and non‐pustular palmoplantar involvement: results from three phase 3 trials (UNCOVER‐1, UNCOVER‐2 and UNCOVER‐3). Journal of the European Academy of Dermatology and Venereology. 31(10). 1686–1692. 53 indexed citations

11.

Blauvelt, Andrew, Kim Papp, Howard Sofen, et al.. (2017). Continuous dosing versus interrupted therapy with ixekizumab: an integrated analysis of two phase 3 trials in psoriasis. Journal of the European Academy of Dermatology and Venereology. 31(6). 1004–1013. 53 indexed citations

12.

Menter, Alan, Kristian Reich, Richard B. Warren, et al.. (2016). 056 Impact of ixekizumab on palmoplantar plaque psoriasis compared to placebo and etanercept: results from UNCOVER 2. Journal of Investigative Dermatology. 136(9). S170–S170. 5 indexed citations

13.

Duffin, Kristina Callis, Michael Bukhalo, David Shrom, et al.. (2016). Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience. Medical Devices Evidence and Research. Volume 9. 361–369. 17 indexed citations

14.

Langley, Richard G., Andrew Blauvelt, Ken Gordon, et al.. (2016). Rapidité d’action de l’ixékizumab : analyse groupée de 2 essais randomisés de phase 3 (UNCOVER-2 et 3) chez des patients atteints de psoriasis. Annales de Dermatologie et de Vénéréologie. 143(12). S397–S397.

15.

Zhu, Baojin, Emily Edson‐Heredia, Gregory S. Cameron, et al.. (2013). Early clinical response as a predictor of subsequent response to ixekizumab treatment: results from a phase II study of patients with moderate-to-severe plaque psoriasis. British Journal of Dermatology. 169(6). 1337–1341. 34 indexed citations

16.

Sarwat, Samiha, Liza L. Ilag, Michelle A. Carey, David Shrom, & Robert J. Heine. (2010). The relationship between self‐monitored blood glucose values and glycated haemoglobin in insulin‐treated patients with Type 2 diabetes. Diabetic Medicine. 27(5). 589–592. 3 indexed citations

17.

Shrom, David, Samiha Sarwat, Liza L. Ilag, & Zachary T. Bloomgarden. (2010). Does A1c consistently reflect mean plasma glucose?. Journal of Diabetes. 2(2). 92–96. 14 indexed citations

18.

Schwartz, Gregory W., et al.. (2007). Detection and prediction of periodic patterns by the retina. Nature Neuroscience. 10(5). 552–554. 72 indexed citations

19.

Feng, Ruiben, Huimin Wang, Jianlin Wang, et al.. (2004). Forebrain degeneration and ventricle enlargement caused by double knockout of Alzheimer's presenilin-1 and presenilin-2. Proceedings of the National Academy of Sciences. 101(21). 8162–8167. 99 indexed citations

20.

Feng, Ruiben, Claire Rampon, Ya‐Ping Tang, et al.. (2001). Deficient Neurogenesis in Forebrain-Specific Presenilin-1 Knockout Mice Is Associated with Reduced Clearance of Hippocampal Memory Traces. Neuron. 32(5). 911–926. 372 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact